Orchestra BioMed Receives $6.1M Milestone from Vivasure Acquisition
Event summary
- Orchestra BioMed received $6.1M on September 14, 2026, as a milestone payment from Haemonetics' acquisition of Vivasure.
- This follows a $5M upfront payment in January 2026, bringing total cash proceeds to $11M.
- Orchestra BioMed remains eligible for up to $10M in additional revenue earnouts, potentially totaling $21M.
- Vivasure's PerQseal® Elite system is a bioabsorbable patch for vessel closure, not yet available in the U.S.
The big picture
Orchestra BioMed's milestone payment underscores the value of its strategic holdings, providing critical capital to support its high-impact technologies. The deal reflects a broader trend in the biomedical sector where companies leverage partnerships to accelerate product development and market penetration. With pivotal trials underway for AVIM Therapy and Virtue SAB, Orchestra BioMed is positioning itself in multi-billion-dollar markets, though its ability to sustain momentum post-milestone will be key.
What we're watching
- Financial Flexibility
- How Orchestra BioMed will deploy the $11M in proceeds to advance its pivotal programs, particularly AVIM Therapy and Virtue SAB.
- Earnout Potential
- Whether Orchestra BioMed can achieve the remaining $10M in revenue earnouts, contingent on Vivasure's performance under Haemonetics.
- Strategic Focus
- The pace at which Orchestra BioMed can transition from monetizing strategic holdings to driving its own product commercialization.
Related topics